CN106456578B - Sigma-1受体激动剂化合物的用途 - Google Patents

Sigma-1受体激动剂化合物的用途 Download PDF

Info

Publication number
CN106456578B
CN106456578B CN201580018235.6A CN201580018235A CN106456578B CN 106456578 B CN106456578 B CN 106456578B CN 201580018235 A CN201580018235 A CN 201580018235A CN 106456578 B CN106456578 B CN 106456578B
Authority
CN
China
Prior art keywords
alkyl
alkoxy
disease
aryl
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580018235.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN106456578A (zh
Inventor
安德里亚·菲克特
亚当·凡耐
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Somerset University
Affiliated Institutes Of Hungarian Academy Of Sciences And Other Institutions
Original Assignee
Somerset University
Affiliated Institutes Of Hungarian Academy Of Sciences And Other Institutions
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Somerset University, Affiliated Institutes Of Hungarian Academy Of Sciences And Other Institutions filed Critical Somerset University
Publication of CN106456578A publication Critical patent/CN106456578A/zh
Application granted granted Critical
Publication of CN106456578B publication Critical patent/CN106456578B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/402—1-aryl substituted, e.g. piretanide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4515—Non condensed piperidines, e.g. piperocaine having a butyrophenone group in position 1, e.g. haloperidol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
CN201580018235.6A 2014-02-07 2015-02-09 Sigma-1受体激动剂化合物的用途 Active CN106456578B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14462004 2014-02-07
EP14462004.4 2014-02-07
PCT/HU2015/000014 WO2015118365A1 (en) 2014-02-07 2015-02-09 Novel use of sigma-1 receptor agonist compounds

Publications (2)

Publication Number Publication Date
CN106456578A CN106456578A (zh) 2017-02-22
CN106456578B true CN106456578B (zh) 2020-02-18

Family

ID=50241356

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580018235.6A Active CN106456578B (zh) 2014-02-07 2015-02-09 Sigma-1受体激动剂化合物的用途

Country Status (13)

Country Link
US (1) US10124006B2 (enExample)
EP (1) EP3104847B8 (enExample)
JP (1) JP6723930B2 (enExample)
CN (1) CN106456578B (enExample)
CA (1) CA2938928C (enExample)
DK (1) DK3104847T3 (enExample)
ES (1) ES2848710T3 (enExample)
HR (1) HRP20210114T1 (enExample)
HU (1) HUE053165T2 (enExample)
IL (1) IL247143B (enExample)
PL (1) PL3104847T3 (enExample)
SI (1) SI3104847T1 (enExample)
WO (1) WO2015118365A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017211765A1 (en) * 2016-06-07 2017-12-14 Laboratorios Del Dr. Esteve, S.A. Sigma ligands for use in the treatment of diabetes and metabolic syndrome
WO2018096376A1 (en) * 2016-11-24 2018-05-31 Mta Támogatott Kutatócsoportok Irodája Compositions for organ preservation
WO2019079794A1 (en) * 2017-10-20 2019-04-25 Anavex Life Sciences Corp. TREATMENT OF CARDIAC DYSFUNCTIONS
EP3893892A4 (en) * 2018-12-12 2022-09-14 Rutgers, the State University of New Jersey Organic compounds
JP7433331B2 (ja) * 2019-02-14 2024-02-19 アルジャーノン・ファーマスーティカルズ・インコーポレイテッド 特発性肺線維症を治療するための組成物及び方法
CN114585364B (zh) 2019-10-28 2025-09-02 塞伊尔特克斯公司 谷氨酸2b受体拮抗剂和σ受体激动剂作为止咳药的用途
CN112386679B (zh) * 2020-11-18 2023-05-30 徐州医科大学 一种包载sigma-1受体的外泌体在制备抗抑郁药物中的应用
US20230263797A1 (en) * 2021-08-26 2023-08-24 Unm Rainforest Innovations Mammalian Hybrid Pre-Autophagosomal Structure HyPAS and Compositions and Methods for the Treatment of Coronavirus Infections and Related Disease States
CN118302423A (zh) * 2022-11-04 2024-07-05 石药集团中奇制药技术（石家庄）有限公司 胺类化合物及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013103317A1 (en) * 2012-01-05 2013-07-11 Clanotech Ab Quinoline compounds which are anti-angiogenic integrin alpha5 betal inhibitors for use in the treatment of fibrosis or fibrosis-related diseases

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7503310A (nl) 1975-03-20 1976-09-22 Philips Nv Verbindingen met antidepressieve werking.
IN186677B (enExample) 1999-11-12 2001-10-20 Sun Pharmaceutical Ind Ltd
US6500835B2 (en) 2000-02-22 2002-12-31 Suntory Limited Preventive or therapeutic drugs for fibrosis containing chymase inhibitors as the active ingredient
AR038002A1 (es) * 2001-11-13 2004-12-22 Schering Corp Antagonistas del receptor de neuroquinina-1, composiciones farmaceuticas y el uso de dichos antagonistas para la preparacion de un medicamento
AR039241A1 (es) 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
CN1688549A (zh) 2002-08-23 2005-10-26 麒麟麦酒株式会社 具有TGFβ抑制活性的化合物和含所述化合物的药用组合物
GB0715047D0 (en) 2007-08-02 2007-09-12 Glaxo Group Ltd Novel Compounds
DE102007063535A1 (de) * 2007-12-21 2009-06-25 Cycnad Gmbh & Co. Kg Pharmazeutische Zusammensetzung zur Prophylaxe und/oder symptomatischen Behandlung von zystischer Fibrose
US20110288134A1 (en) 2008-10-29 2011-11-24 Pacific Therapeutics Ltd. Composition and method for treating fibrosis
EP2391717A1 (en) 2009-01-28 2011-12-07 Aarhus Universitet Treatment of radiation-induced fibrosis
EP2353598A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for use in the prevention and/or treatment of postoperative pain
WO2011146863A1 (en) * 2010-05-21 2011-11-24 Alcon Research, Ltd. Surgical compositions containing sigma-receptor agonists

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013103317A1 (en) * 2012-01-05 2013-07-11 Clanotech Ab Quinoline compounds which are anti-angiogenic integrin alpha5 betal inhibitors for use in the treatment of fibrosis or fibrosis-related diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Fluoxetine inhibited extracellular matrix of pulmonary artery and inflammation of lungs in monocrotaline-treated rats.;Xue-qin LI et al.;《Acta Pharmacologica Sinica》;20111231;第32卷;217–222 *

Also Published As

Publication number Publication date
CA2938928C (en) 2023-01-24
CN106456578A (zh) 2017-02-22
HRP20210114T1 (hr) 2021-04-16
SI3104847T1 (sl) 2021-07-30
IL247143B (en) 2019-10-31
EP3104847B1 (en) 2020-11-11
US10124006B2 (en) 2018-11-13
HUE053165T2 (hu) 2021-06-28
JP6723930B2 (ja) 2020-07-15
US20160346290A1 (en) 2016-12-01
DK3104847T3 (da) 2021-02-01
IL247143A0 (en) 2016-09-29
WO2015118365A1 (en) 2015-08-13
CA2938928A1 (en) 2015-08-13
PL3104847T3 (pl) 2021-07-05
ES2848710T3 (es) 2021-08-11
EP3104847B8 (en) 2020-12-30
JP2017509694A (ja) 2017-04-06
EP3104847A1 (en) 2016-12-21

Similar Documents

Publication Publication Date Title
CN106456578B (zh) Sigma-1受体激动剂化合物的用途
EP3630125A2 (en) Senolytic compounds
CN101426517B (zh) 用于预防和消除组织中纤维样和其他病理性沉积的、含ghrp-6的药物组合物
EA030651B1 (ru) Замещенные ароматические соединения и связанный с ними способ лечения фиброза
Jacobs et al. Endothelial to mesenchymal transition in kidney fibrosis
CA2918340C (en) Rhynchophylline derivatives and their use as epha4 inhibitors for neuroprotection
JP2021500362A (ja) 進行性線維化を伴う間質性肺疾患（ｐｆ−ｉｌｄ）の処置のための活性剤の新規組み合わせ
KR20170141757A (ko) 테트라하이드로나프티리디닐 프로피온산 유도체 및 이의 용도
KR20230002263A (ko) 섬유증 질환의 예방 및 치료를 위한 항-클라우딘-1 단일클론 항체
KR20200115547A (ko) 섬유성 병리를 치료하는 방법
JP2023030022A (ja) 線維症の処置
KR20120023524A (ko) 간 질환의 진단, 치료 및 예방용 조성물
Zhang et al. Asiatic acid from Cyclocarya paliurus regulates the autophagy–lysosome system via directly inhibiting TGF-β type I receptor and ameliorates diabetic nephropathy fibrosis
Kim et al. Antifibrotic effect of Pirfenidone on orbital fibroblasts of patients with thyroid-associated ophthalmopathy by decreasing TIMP-1 and collagen levels
Wang et al. Calcium dobesilate mediates renal interstitial fibrosis and delay renal peritubular capillary loss through Sirt1/p53 signaling pathway
HUE035890T2 (en) VAP-1 inhibitors for use in the treatment of fibrotic conditions
Ruan et al. The IL-33-ST2 axis plays a vital role in endometriosis via promoting epithelial–mesenchymal transition by phosphorylating β-catenin
KR20180007307A (ko) 자가포식 향상물질 및 그 용도
US10842794B2 (en) Use of Sigma-1 receptor agonist compounds
Zang et al. Protective effect of CD137 deficiency against postinfarction cardiac fibrosis and adverse cardiac remodeling by ERK1/2 signaling pathways
US20250282861A1 (en) Mfap4 and treatment of fibrosis
Chen et al. An L-type calcium channel blocker nimodipine exerts anti-fibrotic effects by attenuating TGF-β1 induced calcium response in an in vitro model of thyroid eye disease
Iyer et al. Inhibition of hedgehog signaling ameliorates severity of chronic pancreatitis in experimental mouse models
Eberli et al. Increased autophagy contributes to impaired smooth muscle function in neurogenic lower urinary tract dysfunction
US20250179167A1 (en) Il-6 inhibitor as treatment for nephropathy

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant